The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Targeting AKT for cancer therapy
Open accessAbstract
Introduction: Targeted therapies in cancer aim to inhibit specific molecular targets responsible for enhanced tumor growth. AKT/PKB (protein kinase B) is a serine threonine kinase involved in several critical cellular pathways, including survival, proliferation, invasion, apoptosis, and angiogenesis. Although phosphatidylinositol-3 kinase (PI3K) is the key regulator of AKT activation, numerous stimuli and kinases initiate pro-proliferative AKT signaling which results in the activation of AKT pathway to drive cellular growth and survival. Activating mutations and amplification of components of the AKT pathway are implicated in the pathogenesis of many cancers including breast and ovarian. Given its importance, AKT, it has been validated as a promising therapeutic target.Areas covered: This article summarizes AKT’s biological function and different classes of AKT inhibitors as anticancer agents. We also explore the efficacy of AKT inhibitors as monotherapies and in combination with cytotoxic and other targeted therapies.Expert opinion: The complex mechanism following AKT inhibition requires the addition of other therapies to prevent resistance and improve clinical response. Further studies are necessary to determine additional rational combinations that can enhance efficacy of AKT inhibitors, potentially by targeting compensatory mechanisms, and/or enhancing apoptosis. The identification of biomarkers of response is essential for the development of successful therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301
RetractedIdentification of Akt Interaction Protein PHF20/TZP That Transcriptionally Regulates p53
Park, S., Kim, D., Dan, H. C., Chen, H., Testa, J. R., & Cheng, J. Q. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.333922 · Cited by 29
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Ma, J., & Jemal, A. (2013) · Breast Cancer Metastasis and Drug Resistance · doi:10.1007/978-1-4614-5647-6_1 · Cited by 1,907
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Breast cancer statistics, 2011
DeSantis, C., Siegel, R., Bandi, P., & Jemal, A. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20134 · Cited by 1,326
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Akt, FoxO and regulation of apoptosis
Zhang, X., Tang, N., Hadden, T. J., & Rishi, A. K. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.010 · Cited by 1,103
Lawlor, M. A., & Alessi, D. R. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.16.2903 · Cited by 1,071
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944
Gao, T., Furnari, F., & Newton, A. C. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.008 · Cited by 906
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 821
PI 3-kinase, Akt and cell survival
Downward, J. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2004.01.002 · Cited by 783
Structure, regulation and function of PKB/AKT—a major therapeutic target
Hanada, M., Feng, J., & Hemmings, B. A. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.11.009 · Cited by 719
Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53
Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., & Gotoh, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109745200 · Cited by 617
Morrison, D. K. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.10.003 · Cited by 605
Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size
Easton, R. M., Cho, H., Roovers, K., Shineman, D. W., Mizrahi, M., Forman, M. S., Lee, V. M.-Y., Szabolcs, M., de Jong, R., Oltersdorf, T., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1869-1878.2005 · Cited by 551
Arboleda, M. J., Lyons, J. F., Kabbinavar, F. F., Bray, M. R., Snow, B. E., Ayala, R., Danino, M., Karlan, B. Y., & Slamon, D. J. (2003) · PubMed · Cited by 507
Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase
Feng, J., Park, J., Cron, P., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406731200 · Cited by 488
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 422
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer
Mabuchi, S., Kuroda, H., Takahashi, R., & Sasano, T. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.02.003 · Cited by 413
BARNETT, S. F., DEFEO-JONES, D., FU, S., HANCOCK, P. J., HASKELL, K. M., JONES, R. E., KAHANA, J. A., KRAL, A. M., LEANDER, K., LEE, L. L., et al. (2005) · Biochemical Journal · doi:10.1042/bj20041140 · Cited by 396
Cheon, D.-J., & Orsulic, S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.154244 · Cited by 395
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Unravelling the activation mechanisms of protein kinase B/Akt
Scheid, M. P., & Woodgett, J. R. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00562-3 · Cited by 390
Physiological roles of PKB/Akt isoforms in development and disease
Dummler, B., & Hemmings, B. A. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350231 · Cited by 316
Pathogenesis and heterogeneity of ovarian cancer
Kroeger, P. T., & Drapkin, R. (2017) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000340 · Cited by 314
AKT Inhibition in Solid Tumors With AKT1 Mutations
Hyman, D. M., Smyth, L. M., Donoghue, M. T. A., Westin, S. N., Bedard, P. L., Dean, E. J., Bando, H., El-Khoueiry, A. B., Pérez-Fidalgo, J. A., Mita, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0143 · Cited by 311
Lin, J., Sampath, D., Nannini, M. A., Lee, B. B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 294
MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis
Xu, Q., Liu, L.-Z., Qian, X., Chen, Q., Jiang, Y., Li, D., Lai, L., & Jiang, B.-H. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr730 · Cited by 284
AKT signaling in normal and malignant cells
Testa, J. R., & Tsichlis, P. N. (2005) · Oncogene · doi:10.1038/sj.onc.1209100 · Cited by 274
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
Evidence That Ser87 of BimEL Is Phosphorylated by Akt and Regulates BimEL Apoptotic Function
Qi, X.-J., Wildey, G. M., & Howe, P. H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m505546200 · Cited by 234
Addie, M., Ballard, P., Buttar, D., Crafter, C., Currie, G., Davies, B. R., Debreczeni, J., Dry, H., Dudley, P., Greenwood, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301762v · Cited by 230
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
van Zyl, B., Tang, D., & Bowden, N. A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0336 · Cited by 230
Xing, Y., Lin, N. U., Maurer, M. A., Chen, H., Mahvash, A., Sahin, A., Akcakanat, A., Li, Y., Abramson, V., Litton, J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1154-8 · Cited by 220
Self-citationPI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke-Hale, K., Sahin, A., Liu, S., Barrera, J. A., Burgues, O., Lluch, A. M., Chen, H., Hortobagyi, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1089 · Cited by 219
Self-citationBlake, J. F., Xu, R., Bencsik, J. R., Xiao, D., Kallan, N. C., Schlachter, S., Mitchell, I. S., Spencer, K. L., Banka, A. L., Wallace, E. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301024w · Cited by 191
Fan, W., Chang, J., & Fu, P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.93 · Cited by 174
Saura, C., Roda, D., Roselló, S., Oliveira, M., Macarulla, T., Pérez-Fidalgo, J. A., Morales-Barrera, R., Sanchis-García, J. M., Musib, L., Budha, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0512 · Cited by 172
A systematic review of dual targeting in HER2-positive breast cancer
Kümler, I., Tuxen, M. K., & Nielsen, D. L. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.09.002 · Cited by 169
Opposing Roles for Akt1 and Akt2 in Rac/Pak Signaling and Cell Migration
Zhou, G.-L., Tucker, D. F., Bae, S. S., Bhatheja, K., Birnbaum, M. J., & Field, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600788200 · Cited by 163
Tolcher, A. W., Patnaik, A., Papadopoulos, K. P., Rasco, D. W., Becerra, C. R., Allred, A. J., Orford, K., Aktan, G., Ferron-Brady, G., Ibrahim, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2615-5 · Cited by 158
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
Sangai, T., Akcakanat, A., Chen, H., Tarco, E., Wu, Y., Do, K.-A., Miller, T. W., Arteaga, C. L., Mills, G. B., Gonzalez-Angulo, A. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1141 · Cited by 158
Self-citationDumble, M. L., Crouthamel, M., Zhang, S., Schaber, M. D., Levy, D. S., Robell, K. A., Liu, Q., Figueroa, D. J., Minthorn, E. A., Seefeld, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100880 · Cited by 151
Akt as a therapeutic target in cancer
Steelman, L. S., Stadelman, K. M., Chappell, W. H., Horn, S., Bäsecke, J., Cervello, M., Nicoletti, F., Libra, M., Stivala, F., Martelli, A. M., et al. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.9.1139 · Cited by 149
Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood · doi:10.1182/blood-2014-03-559963 · Cited by 142
Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Altomare, D. A., & Khaled, A. R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712801661130 · Cited by 137
Lapierre, J., Eathiraj, S., Vensel, D., Liu, Y., Bull, C. O., Cornell-Kennon, S., Iimura, S., Kelleher, E. W., Kizer, D. E., Koerner, S. K., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00619 · Cited by 126
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Yu, Y., Savage, R. E., Eathiraj, S., Meade, J., Wick, M. J., Hall, T. G., Abbadessa, G., & Schwartz, B. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140479 · Cited by 123
Conus, N. M., Hannan, K. M., Cristiano, B. E., Hemmings, B. A., & Pearson, R. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203387200 · Cited by 114
Suppression of survival signalling pathways by the phosphatase PHLPP
O’Neill, A., Niederst, M. J., & Newton, A. C. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08537.x · Cited by 113
Cristiano, B. E., Chan, J. C., Hannan, K. M., Lundie, N. A., Marmy-Conus, N., Campbell, I., Phillips, W. A., Robbie, M. J., Hannan, R. D., & Pearson, R. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1968 · Cited by 101
Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective
Singh, M., & Johnson, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0437 · Cited by 98
Berndt, N., Yang, H., Trinczek, B., Betzi, S., Zhang, Z., Wu, B., Lawrence, N. J., Pellecchia, M., Schönbrunn, E., Cheng, J. Q., et al. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.63 · Cited by 93
A Phase 2 study of perifosine in advanced or metastatic breast cancer
Leighl, N. B., Dent, S. F., Clemons, M. J., Vandenberg, T. A., Tozer, R. G., Warr, D. G., Crump, R. M., Hedley, D. W., Pond, G. R., Dancey, J. E., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9584-x · Cited by 91
Stewart, S. L., Harewood, R., Matz, M., Rim, S. H., Sabatino, S. A., Ward, K. C., & Weir, H. K. (2017) · Cancer · doi:10.1002/cncr.31027 · Cited by 84
Garrett, C. R., Coppola, D., Wenham, R. M., Cubitt, C. L., Neuger, A. M., Frost, T. J., Lush, R. M., Sullivan, D. M., Cheng, J. Q., & Sebti, S. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9479-2 · Cited by 79
Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
Yi, K. H., & Lauring, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6648 · Cited by 77
Davies, B. R., Guan, N., Logié, A., Crafter, C., Hanson, L. L., Jacobs, V. N., James, N. H., Dudley, P., Jacques, K., Ladd, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0230 · Cited by 76
Ma, C. X., Suman, V. J., Goetz, M. P., Northfelt, D., Burkard, M. E., Ademuyiwa, F. O., Naughton, M., Margenthaler, J. A., Aft, R., Gray, R. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1260 · Cited by 75
AKT signaling in ERBB2-amplified breast cancer
Carmona, F. J., Montemurro, F., Kannan, S., Rossi, V., Verma, C. S., Baselga, J. M., & Scaltriti, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.013 · Cited by 74
Preclinical testing of the Akt inhibitor triciribine in T‐cell acute lymphoblastic leukemia
Evangelisti, C., Ricci, F., Tazzari, P. L., Chiarini, F., Battistelli, M., Falcieri, E., Ognibene, A., Pagliaro, P., Cocco, L., McCubrey, J. A., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22407 · Cited by 70
McLaughlin, J. R., Markovtsov, V. V., Li, H., Wong, S., Gelman, M. S., Zhu, Y., Franci, C., Lang, D. W., Pali, E. S., Lasaga, J., et al. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0641-1 · Cited by 70
Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
Lindhurst, M. J., Yourick, M. R., Yu, Y., Savage, R. E., Ferrari, D., & Biesecker, L. G. (2015) · Scientific Reports · doi:10.1038/srep17162 · Cited by 67
Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
Monk, B. J., & Coleman, R. L. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c104fa · Cited by 65
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
Stottrup, C., Tsang, T., & Chin, Y. R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0748 · Cited by 65
Politz, O., Siegel, F., Bärfacker, L., Bömer, U., Hägebarth, A., Scott, W. J., Michels, M., Ince, S. J., Neuhaus, R., Meyer, K., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30457 · Cited by 61
Schmid, P., Abraham, J., Chan, S. Y. T., Wheatley, D. A., Brunt, M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.1007 · Cited by 61
Shi, Y., Liu, X., Han, E. K.-H., Guan, R., Shoemaker, A. R., Oleksijew, A., Woods, K. W., Fisher, J. P., Klinghofer, V., Lasko, L. M., et al. (2005) · Neoplasia · doi:10.1593/neo.05355 · Cited by 58
Aghajanian, C. A., Bell‐McGuinn, K. M., Burris, H. A., Siu, L. L., Stayner, L.-A., Wheler, J. J., Hong, D. S., Kurkjian, C. D., Pant, S., Santiago-Walker, A., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0591-z · Cited by 58
Akt inhibitors: mechanism of action and implications for anticancer therapeutics
Bhutani, J., Sheikh, A., & Niazi, A. K. (2013) · Infectious Agents and Cancer · doi:10.1186/1750-9378-8-49 · Cited by 47
The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL‐induced apoptosis
Dieterle, A. M., Orth, R., Daubrawa, M., Grotemeier, A., Alers, S., Ullrich, S., Lammers, R., Wesselborg, S., & Stork, B. (2009) · International Journal of Cancer · doi:10.1002/ijc.24374 · Cited by 46
AKT isoform-specific expression and activation across cancer lineages
Wang, J., Zhao, W., Guo, H., Fang, Y., Stockman, S., Bai, S., Ng, P. K., Yang, L., Yu, Q., Lu, Y., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4654-5 · Cited by 46
SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer
Gonzalez-Angulo, A. M., Krop, I. E., Akçakanat, A., Chen, H., Liu, S., Li, Y., Culotta, K. S., Tarco, E., Piha-Paul, S. A., Moulder-Thompson, S. L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju493 · Cited by 41
Self-citationAzaro, A., Rodon, J. A., Calles, A., Braña, I., Hidalgo, M. M., Lopez-Casas, P. P., Muñoz, M., Westwood, P., Miller, J. A., Moser, B. A., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0241-7 · Cited by 35
Machl, A. W., Wilker, E., Tian, H., Liu, X., Schroeder, P. E., Clark, A., & Huck, B. R. (2016) · PubMed · Cited by 35
Functional specificity of Akt isoforms in cancer progression
Fortier, A.-M., Asselin, É., & Cadrin, M. (2011) · BioMolecular Concepts · doi:10.1515/bmc.2011.003 · Cited by 32
Li, X. J., Leem, S., Park, M. H., & Kim, S. M. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2121 · Cited by 31
Tripathy, D., Chien, A. J., Hylton, N. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.524 · Cited by 31
Kalinsky, K. M., Sparano, J. A., Zhong, X., et al. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1888-2 · Cited by 29
Renshaw, J., Patnaik, A., Gordon, M. S., Beeram, M., Fischer, D., Gianella-Borradori, A., Lin, C., & Mendelson, D. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14130 · Cited by 26
Kariche, N., Hortal, M. T., Benyahia, S., Alemany, L., Moulaï, N., Clavero, O., Muñoz, M. C., Ouahioune, W., Djennaoui, D., Touil–Boukoffa, C., et al. (2018) · Infectious Agents and Cancer · doi:10.1186/s13027-018-0181-x · Cited by 26
Angevin, E., Cassier, P. A., Italiano, A., Gonçalvès, A., Gazzah, A., Terret, C., Toulmonde, M., Gravis, G., Varga, A., Parlavecchio, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.036 · Cited by 21
Crosstalk in transition: the translocation of Akt
Gray, C. W., & Coster, A. C. F. (2018) · Journal of Mathematical Biology · doi:10.1007/s00285-018-1297-8 · Cited by 12
The PI3K Pathway as a Therapeutic Target in Breast Cancer
Ma, C. X. (2015) · American Journal of Hematology / Oncology® · Cited by 11
Tolcher, A. W., Harb, W. A., Sachdev, J. C., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30201-5 · Cited by 8
Tsimberidou, A. M., Verschraegen, C. F., Heestand, G. M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv094.1 · Cited by 5
(2010) · PubMed Central
Cited by
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
Liu, R., Chen, Y., Liu, G., Li, C., Song, Y., Cao, Z., Li, W., Hu, J., Lu, C., & Liu, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02998-6 · Cited by 923
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Neophytou, C. M., Trougakos, I. P., Erin, N., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13174363 · Cited by 371
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
Li, Q., Li, Z., Luo, T., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00110-2 · Cited by 264
PH domain-mediated autoinhibition and oncogenic activation of Akt
Bae, H., Viennet, T., Park, E., Chu, N., Salguero, A., Eck, M. J., Arthanari, H., & Cole, P. A. (2022) · eLife · doi:10.7554/elife.80148 · Cited by 31
Metadata
- Authors
- Shariati, M., & Meric-Bernstam, F.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2019-10-12
- Volume
- 28
- Issue
- 11
- Pages
- 977-988
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2979668391
- Cited by
- 290
- References
- 100
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.